EuroBiotech: More Articles of Note


> Oxurion’s THR-317 failed to improve vision in patients with diabetic macular edema in a phase 2a trial. The antibody against placental growth factor was no better than placebo in the overall population, but Oxurion highlighted a “certain improvement” in pre-specified subgroups. Statement  

> Abivax enrolled the first patient in its ulcerative colitis phase 2b trial. Top-line data are due next year. Release 

> Redx Pharma finished dosing the first cohort of patients in a phase 1/2 trial of oral porcupine inhibitor RXC004. Enrollment of the second cohort, which will receive a higher dose, is underway. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Motif Bio revealed the National Institutes of Health is funding preclinical testing of iclaprim against Listeria monocytogenes. Release

> Scancell withdrew an IND filing for SCIB1. The FDA held up the start of the trial by requesting extra information, leading Scancell to drop the IND so enrollment in the U.K. can begin. Statement 

Suggested Articles

Akcea CEO Paula Soteropoulos, Chief Business Officer Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.

Weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul.

The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.